Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine
Several countries already are calling about orders, as the company prepares to begin a Phase III trial of its mRNA coronavirus vaccine candidate.
You may also be interested in...
The US government’s order of 100 million doses for $1.95bn means the implied price for Pfizer/BioNtech's vaccine is $19.50 per dose. That could set a benchmark for solid near-term revenue and profitability for companies in the space.
CBER Director Marks explains that too high a bar might result natural herd immunity before vaccine trials could be completed, while too low a threshold could result in approval of products with limited efficacy.
Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.